Acadian Asset Management
MRNA icon

Acadian Asset Management’s Moderna MRNA Stock Holding History

Acadian Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,380
Closed -$677K – 2142
2026
Q1 		$677K Sell
13,380
-70,028
-84% -$3.27M ﹤0.01% 1282
2025
Q4 		$2.46M Sell
83,408
-148,207
-64% -$4.03M ﹤0.01% 857
2025
Q3 		$5.98M Sell
231,615
-412,956
-64% -$11.5M 0.01% 601
2025
Q2 		$17.8M Buy
644,571
+477,072
+285% +$12.6M 0.04% 334
2025
Q1 		$4.75M Buy
167,499
+126,961
+313% +$4.51M 0.01% 516
2024
Q4 		$1.68M Buy
+40,538
New +$1.94M ﹤0.01% 808
2024
Q3 		– Sell
-7,585
Closed -$900K – 2255
2024
Q2 		$900K Buy
+7,585
New +$960K ﹤0.01% 1030
2024
Q1 		– Sell
-4,603
Closed -$457K – 1707
2023
Q4 		$457K Buy
4,603
+3,881
+538% +$326K ﹤0.01% 1042
2023
Q3 		$74K Sell
722
-1,952
-73% -$218K ﹤0.01% 1361
2023
Q2 		$324K Sell
2,674
-1,706
-39% -$228K ﹤0.01% 1162
2023
Q1 		$672K Buy
4,380
+121
+3% +$20K ﹤0.01% 981
2022
Q4 		$764K Sell
4,259
-8,288
-66% -$1.36M ﹤0.01% 913
2022
Q3 		$1.48M Buy
12,547
+6,061
+93% +$920K 0.01% 706
2022
Q2 		$927K Buy
6,486
+26
+0.4% +$3.72K ﹤0.01% 838
2022
Q1 		$1.11M Sell
6,460
-1,291
-17% -$217K ﹤0.01% 807
2021
Q4 		$1.97M Sell
7,751
-2,691
-26% -$787K 0.01% 661
2021
Q3 		$4.01M Sell
10,442
-8,867
-46% -$3.27M 0.02% 509
2021
Q2 		$4.54M Buy
19,309
+11,415
+145% +$2.04M 0.02% 489
2021
Q1 		$1.03M Buy
7,894
+3,475
+79% +$504K ﹤0.01% 942
2020
Q4 		$461K Hold
4,419
– – ﹤0.01% 1258
2020
Q3 		$313K Buy
4,419
+1,193
+37% +$83.2K ﹤0.01% 1289
2020
Q2 		$208K Buy
+3,226
New +$177K ﹤0.01% 1472

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Acadian Asset Management's MRNA Position: Q2 2026 in Review

Acadian Asset Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 13,380 shares — an estimated $677K sold.

Acadian Asset Management first reported a position in MRNA in Q2 2020 and held it in 22 quarters. The position peaked at $17.8M in Q2 2025. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Acadian Asset Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 13,380 Moderna shares in Q2 2026, an estimated $677K.
  • Acadian Asset Management first reported a position in Moderna in Q2 2020 and held it in 22 quarters.
  • Acadian Asset Management's Moderna position peaked at $17.8M in Q2 2025.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.